Literature DB >> 20013079

Effect of auxiliary substances on complexation efficiency and intrinsic dissolution rate of gemfibrozil-beta-CD complexes.

Fareen Sami1, Betty Philip, Kamla Pathak.   

Abstract

The studies reported in this work are aimed to elucidate the ternary inclusion complex formation of gemfibrozil (GFZ), a poorly water-soluble drug, with beta-cyclodextrin (beta-CD) with the aid of auxiliary substances like different grades of povidone(s) (viz. PVP K-29/32, PVP K-40, Plasdone S-630, and Polyplasdone XL), organic base (viz. triethanolamine), and metal ion (viz. MgCl(2).6H(2)O), by investigating their interactions in solution and solid state. Phase solubility studies were carried out to evaluate the solubilizing power of beta-cyclodextrin, in association with various auxiliary substances, to determine the apparent stability constant (K (C)) and complexation efficiency (CE) of complexes. Improvement in K (C) values for ternary complexes clearly proves the benefit of the addition of auxiliary substances to promote CE. Of all the approaches used, the use of polymer Plasdone S-630 was found to be the most promising approach in terms of optimum CE and K (C). GFZ-beta-CD (1:1) binary and ternary systems were prepared by kneading and lyophilization methods. The ternary systems clearly signified superiority over binary systems in terms of CE, solubility, K (C), and reduction in the formulation bulk. Optimized ternary system of GFZ-beta-CD-Plasdone S-630 prepared by using lyophilization method indicated a significant improvement in intrinsic dissolution rate when compared with ternary kneaded system. Differential scanning calorimetry, X-ray diffraction, Fourier transform infrared, scanning electron microscopy, and proton nuclear magnetic resonance were carried out to characterize the binary and optimized ternary complex. The results suggested the formation of new solid phases, eliciting strong evidences of ternary inclusion complex formation between GFZ, beta-CD, and Plasdone S-630, particularly for lyophilized products.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20013079      PMCID: PMC2850474          DOI: 10.1208/s12249-009-9350-y

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  17 in total

1.  Inclusion compounds of non-steroidal antiinflammatory and other slightly water soluble drugs with alpha- and beta-cyclodextrins in powdered form.

Authors:  M Kurozumi; N Nambu; T Nagai
Journal:  Chem Pharm Bull (Tokyo)       Date:  1975-12       Impact factor: 1.645

2.  Compressed pellet X-ray diffraction monitoring for optimization of crystallinity in lyophilized solids: imipenem: cilastatin sodium case.

Authors:  J A Ryan
Journal:  J Pharm Sci       Date:  1986-08       Impact factor: 3.534

3.  Influence of hydrophilic polymers on celecoxib complexation with hydroxypropyl beta-cyclodextrin.

Authors:  Kora Pattabhi Ramaiah Chowdary; Sekuboyina Vijaya Srinivas
Journal:  AAPS PharmSciTech       Date:  2006-09-29       Impact factor: 3.246

Review 4.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.

Authors:  T Loftsson; M E Brewster
Journal:  J Pharm Sci       Date:  1996-10       Impact factor: 3.534

5.  Diclofenac-beta-cyclodextrin binary systems: physicochemical characterization and in vitro dissolution and diffusion studies.

Authors:  Maria Letizia Manca; Marco Zaru; Guido Ennas; Donatella Valenti; Chiara Sinico; Giuseppe Loy; Anna Maria Fadda
Journal:  AAPS PharmSciTech       Date:  2005-10-22       Impact factor: 3.246

Review 6.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

7.  Improvement in solubility and dissolution rate of 1, 2-dithiole-3-thiones upon complexation with beta-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives.

Authors:  G Dollo; P Le Corre; M Chollet; F Chevanne; M Bertault; J L Burgot; R Le Verge
Journal:  J Pharm Sci       Date:  1999-09       Impact factor: 3.534

8.  Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with beta-cyclodextrin and its sulfobutyl ether derivative in solution and solid state.

Authors:  Laura S S Ribeiro; Domingos C Ferreira; Francisco J B Veiga
Journal:  Eur J Pharm Sci       Date:  2003-11       Impact factor: 4.384

9.  The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-beta-cyclodextrin.

Authors:  Granero Gladys; Garnero Claudia; Longhi Marcela
Journal:  Eur J Pharm Sci       Date:  2003-11       Impact factor: 4.384

10.  Influence of preparation methodology on solid-state properties of an acidic drug-cyclodextrin system.

Authors:  Ramprakash Govindarajan; Mangal S Nagarsenker
Journal:  J Pharm Pharmacol       Date:  2004-06       Impact factor: 3.765

View more
  4 in total

1.  Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances.

Authors:  Kale Mohana Raghava Srivalli; Brahmeshwar Mishra
Journal:  AAPS PharmSciTech       Date:  2015-06-16       Impact factor: 3.246

2.  Cavamax W7 composite psoralen ethosomal gel versus cavamax W7 psoralen solid complex gel for topical delivery: A comparative evaluation.

Authors:  Smriti Kumari; Kamla Pathak
Journal:  Int J Pharm Investig       Date:  2013-10

3.  Formulation and Evaluation of Supramolecular Food-Grade Piperine HP β CD and TPGS Complex: Dissolution, Physicochemical Characterization, Molecular Docking, In Vitro Antioxidant Activity, and Antimicrobial Assessment.

Authors:  Syed Sarim Imam; Sultan Alshehri; Talal Abdullah Alzahrani; Afzal Hussain; Mohammad A Altamimi
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

4.  Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste.

Authors:  Samia M Omar; Fares Ibrahim; Aliaa Ismail
Journal:  Saudi Pharm J       Date:  2020-02-03       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.